After FDA Setback, Zydus’ CUTX‑101 Stages a High‑Stakes Comeback with Fresh PDUFA Date

CUTX‑101 back on FDA review track

CUTX‑101, licensed by Zydus’ US arm Sentynl, is being developed as a disease‑modifying treatment for Menkes disease, a rare, often fatal pediatric disorder caused by impaired copper transport. The FDA’s acceptance of the NDA resubmission means the file is again under active review, with January 14, 2026 set as the Prescription Drug User Fee Act (PDUFA) target date for a decision. This follows a prior Complete Response Letter that flagged primarily chemistry, manufacturing and controls (CMC) and inspection observations rather than fundamental efficacy or safety concerns.

 

Key highlights

The resubmission is being reviewed under a shortened clock, reflecting that it directly addresses deficiencies cited in the earlier letter and does not require new large clinical trials.

 

Zydus and Sentynl have implemented remediation measures at the identified manufacturing site, aiming to bring it in full compliance with current good manufacturing practices and satisfy all CMC queries.

 

If approved, CUTX‑101 would become the first FDA‑approved therapy specifically for Menkes disease and could qualify for rare pediatric disease incentives, creating both a high‑impact orphan asset for Zydus and a meaningful new option for affected infants and caregivers.

 

Sources: Company regulatory update, partner announcements, and public US FDA/industry disclosures